Dalal AA, Patel JP, D'Souza A, Farrelly E, Nagar S, Shah M. Impact of COPD exacerbation frequency on costs for a managed care population. J Manag Care Pharm. 2015 Jul;21(7):575-83.
Korsnes JS, Davis KL, Ariely R, Bell C, Mitra D. Health care resource utilization and costs associated with nonfatal major adverse cardiovascular events. J Manag Care Pharm. 2015 Jun;21(6):443-50.
DaCosta Byfield S, McPheeters JT, Burton T, Nagar SP, Hackshaw MD. Persistence and compliance among US patients receiving pazopanib or sunitinib as first-line therapy for advanced renal cell carcinoma. J Manag Care Pharm. 2015 Jun;21(6):515-22.
Maglinte G, Graham C, Schwartzberg L, Price T, Knox H, Hechmati G, Hjelmgren J, Barber B, Fakih M. Economic analysis of panitumumab versus cetuximab in chemorefractory patients with wild-type KRAS metastatic colorectal cancer. Poster presented at the 2015 AMCP Managed Care & Specialty Pharmacy Annual Meeting; April 9, 2015. San Diego, CA. [abstract] J Manag Care Pharm. 21(4a):S11-2.
Wilson M, Mody R, Ursan I, Carr S. The budgetary impact of vedolizumab in the management of moderately to severely active ulcerative colitis and Crohn's disease in the United States. Poster presented at the 2015 AMCP Managed Care & Specialty Pharmacy Annual Meeting; April 7, 2015. San Diego, CA. [abstract] J Manag Care Pharm. 21(4a):S57.
Patel J, Coleman A, Wilson M, McDade C, Carr S, Earnshaw S. Budgetary impact on a U.S. health plan after adopting umeclidinium/vilanterol (UMEC/VI) for the management of moderate-to-severe COPD. Poster presented at the 2015 AMCP Managed Care & Specialty Pharmacy Annual Meeting; April 7, 2015. San Diego, CA. [abstract] J Manag Care Pharm. 2015 Apr 7; 21(4a):S55.
Wang T, Meyers J, Davis K, Madhwani S, Boklage S. Patterns of H. pylori treatment and testing for patients in a commercially insured population. Poster presented at the 2015 AMCP Managed Care & Specialty Pharmacy Annual Meeting; April 1, 2015. San Diego, CA. [abstract] J Manag Care Pharm. 2015 Apr; 21(4-a):S11.
Talbird SE, Graham JB, Mauskopf JA, Masseria C, Krishnarajah G. Impact of tetanus, diphtheria, and acellular pertussis (Tdap) vaccine use in wound management on health care costs and pertussis cases. J Manag Care Pharm. 2015 Jan;21(1):88-99.
Hansen RN, Hackshaw MD, Nagar SP, Arondekar B, Deen KC, Sullivan SD, Ramsey SD. Health care costs among renal cancer patients using pazopanib and sunitinib. J Manag Care Pharm. 2015 Jan;21(1):37-44.
Poulos C, Hauber AB, González JM, Turpcu A. Patients' willingness to trade off between the duration and frequency of rheumatoid arthritis treatments. Arthritis Care Res (Hoboken). 2014 Jul;66(7):1008-15. doi: 10.1002/acr.22265
Hackshaw MD, Nagar SP, Parks DC, Miller LA. Persistence and compliance with Pazopanib in patients with advanced renal cell carcinoma within a U.S. administrative claims database. J Manag Care Pharm. 2014 Jun;20(6):603-10.
Luciano JV, Aguado J, Serrano-Blanco A, Calandre EP, Rodriguez-Lopez CM. Dimensionality, reliability, and validity of the revised fibromyalgia impact questionnaire in two Spanish samples. Arthritis Care Res (Hoboken). 2013 Oct;65(10):1682-9.
Nordstrom BL, Mines D, Gu Y, Mercaldi C, Aquino P, Harrison MJ. Risk of malignancy in children with juvenile idiopathic arthritis not treated with biologic agents. Arthritis Care Res (Hoboken). 2012 Sep;64(9):1357-64. doi: 10.1002/acr.21709
Brown TM, Siu K, Walker D, Pladevall-Vila M, Sander S, Mordin M. Development of a conceptual model of adherence to oral anticoagulants to reduce risk of stroke in patients with atrial fibrillation. J Manag Care Pharm. 2012 Jun 1;18(5):351-62.
Solomon DH, Glynn RJ, Rothman KJ, Schneeweiss S, Setoguchi S, Mogun H, Avorn J, Sturmer T. Subgroup analyses to determine cardiovascular risk associated with nonsteroidal antiinflammatory drugs and coxibs in specific patient groups. Arthritis Care Res (Hoboken). 2008 Aug 15;59(8):1097-104.
Mease P, Arnold L, Crofford L, Williams D, Russell IJ, Humphrey L, Abetz L, Martin SA. Identifying the clinical domains of fibromyalgia: contributions from clinician and patient delphi exercises. Arthritis Care Res (Hoboken). 2008 Jul;59(7):952-60.
Bell C, Graham JB, Earnshaw S, Oleen-Burkey MK, Castelli-Haley J, Johnson K. Cost-effectiveness of four immunomodulatory therapies for relapsing-remitting multiple sclerosis: a Markov model based on long-term clinical data. J Manag Care Pharm. 2007 Apr 1;13(3):245-61.
Strickland A, Brogan AJ, Krauss J, Martindale R, Cresci G. Is the use of specialized nutritional formulations a cost-effective strategy? A national database evaluation. J Parenter Enter Nutr. 2005 Jan 1;29(1 Suppl):S81-91.
Ackerman SJ, Mordin M, Reblando J, Xu X, Schein J, Vallow S, Brennan M. Patient-reported utilization patterns of fentanyl transdermal system and oxycodone hydrochloride controlled-release among patients with chronic nonmalignant pain. J Manag Care Pharm. 2003 May 1;9(3):223-31.